Roche Holding AG (FRA:RHO) FFO


FRA:RHO Roche Holding AG FRA:RHO
78 GF Score
Price €367.20
GF Value €290.54
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Roche Holding AG FFO?

FFO (Funds from operations) only applies to REITs.

FRA:RHO
78GF Score
Roche Holding AG FRA:RHO
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Roche Holding AG (FRA:RHO) Overvalued in 2026?

Based on GuruFocus' analysis, Roche Holding AG stock appears to be overvalued. The current stock price of €367.20 is trading 26.4% above its estimated GF Value™ of €290.54. GuruFocus considers Roche Holding AG to be Modestly Overvalued.

Key valuation signals for FRA:RHO:

  • FFO:
  • GF Value™: €290.54 vs. price of €367.20 (26.4% above fair value)
  • GF Score™: 78/100 with 3 warning signs

No single metric tells the full story. See the FRA:RHO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Roche Holding AG Business Description

Address Grenzacherstrasse 124, Basel, CHE, 4070
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
78GF Score

Get the complete analysis for FRA:RHO

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€367.20
Price
€290.54
GF Value